Actualización del manejo integral terapéutico de la enfermedad renal diabética

Abstract

Introduction: Diabetic kidney disease (DKD) is considered a renal complication of great importance, especially long-term of mainly type 2 diabetes mellitus, likewise it is the main condition for the development of chronic kidney disease (CKD) and especially terminal condition, globally. It affects about 40% of patients with DM2 and 30% of patients with DM1. Objective: To identify the new perspectives of the therapeutic approach to diabetic kidney disease, through the analysis of scientific information of evidence-based medicine, for an adequate therapeutic understanding, and to decrease its progression, improving the quality of life of the population. Methodology: The present study is a systematic bibliographic review of different scientific articles from the last 5 years, of evidence-based medicine, from multiple high-impact digital repositories in health (Scopus, Pubmed, Medigraphic, Elsevier, Cochrane) and scientific literature in internal medicine, endocrinology and nephrology. Conclusion: At present there are new specific drugs with a greater tendency to nephroprotection, among the recently appeared hypoglycemic agents with great renal and cardiovascular potential are SGLT2 inhibitors, GLP 1 inhibitors and DPP 4 inhibitors; these pharmacological groups in a single or combined therapy in synergy, have demonstrated an important clinical quality in the renal and cardiovascular profile, improving the quality of life of the diabetic population, and even non-diabetic.